drugset / Trial / NCT00998322
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with gemcitabine is effective and safe in the treatment of patients with advanced pancreatic cancer.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-12
- Completion
- 2015-02
Outcome
Met primary endpoint
release “advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint” oncolyticsbiotech.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Subject | REOLYSIN® | Other / unclassified | 1e+10 unknown | Intravenous |